Abstract
Dendritic cells (DC) play a key role in the initiation of primary immune response, and pilot clinical studies have demonstrated their ability to induce efficient antitumor immunity. However, the DC used in these clinical trials were generated with various serum sources and were poorly characterized. Obtaining fully characterized DC in controlled and reproducible culture conditions is thus of major interest. We demonstrate that X-VIVO 15 medium supplemented with 2% human albumin can be used to obtain DC. The phenotypic and functional characteristics of these clinical-grade DC were analyzed according to their differentiation stages. CD83−immature DC, obtained in the presence of granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, were able to endocyte soluble antigens and internalize apoptotic tumor cells, and also expressed receptors for inflammatory chemokines. Tumor necrosis factor-α (TNF-α) induced irreversible DC maturation in association with a decreased ability to uptake antigens and an increased allostimulatory capacity. CD83+ mature DC became responsive to EBl1 ligand chemokine (ELC), a chemokine specifically expressed in secondary lymphoid organs. In addition, mature DC obtained with TNF-α produced IL-12 and some IL-10 in response to CD40 stimulation. In conclusion, we present well-defined culture conditions allowing the control of DC maturation for clinical or fundamental studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nature Med 1998 4: 328–332
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G . Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 1999 190: 1669–1678
Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A . Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen Prostate 1996 29: 371–380
Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP . Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides Prostate 1998 36: 39–44
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R . Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells Nature Med 1996 2: 52–58
Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M . CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer (letter) Lancet 1998 352: 1358
Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M . Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells J Urol 1999 161: 777–782
Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R . Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study Blood 1999 93: 2411–2419
Hart DNJ . Dendritic cells: unique leukocyte populations which control the primary immune response Blood 1997 90: 3245–3287
Banchereau J, Steinman RM . Dendritic cells and the control of immunity Nature 1998 392: 245–252
Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, Graziano RF, Pfefferkorn LC, Guyre PM . Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells J Immunol 1997 158: 3090–3098
Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM . Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells J Immunol 1996 157: 541–548
Sallusto F, Cella M, Danieli C, Lanzavecchia A . Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products J Exp Med 1995 182: 389–400
Albert ML, Pearce SFA, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N . Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes J Exp Med 1998 188: 1359–1368
Sozzani S, Allavena P, D'Amico G, Luini W, Bianchi G, Kataura M, Imai T, Yoshie O, Bonecchi R, Mantovani A . Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties J Immunol 1998 161: 1083–1086
Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A . Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation Eur J Immunol 1998 28: 2760–2769
Lin CL, Suri RM, Rahdon RA, Austyn JM, Roake JA . Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation Eur J Immunol 1998 28: 4114–4122
Chan VW, Kothakota S, Rohan MC, Panganiban-Lustan L, Gardner JP, Wachowicz MS, Winter JA, Williams LT . Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells Blood 1999 93: 3610–3616
Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G . Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability J Immunol Methods 1996 196: 137–151
Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N . A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells Blood 1997 90: 3640–3646
Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH . Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions Eur J Immunol 1997 27: 3135–3142
Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G . Generation of large number of fully mature and stable dendritic cells from leukapheresis products for clinical application J Immunol Methods 1999 223: 1–15
Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, Furukawa T, Aoki S, Aizawa Y . Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients Leukemia 1999 13: 166–174
Soruri A, Fayyazi A, Gieseler R, Schlott T, Runger TM, Neumann C, Peters JH . Specific autologous anti-melanoma T cell response in vitro using monocyte-derived dendritic cells Immunobiology 1998 198: 527–538
Anton D, Dabadghao S, Palucka K, Holm G, Yi Q . Generation of dendritic cells from peripheral blood adherent cells in medium with human serum Scand J Immunol 1998 47: 116–121
Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM . Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro J Immunother 1997 20: 276–286
Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M . Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production J Exp Med 1997 186: 1603–1608
Apostolopoulos V, Osinski C, McKenzie IF . MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral Nature Med 1998 4: 315–320
Abdel-Wahab Z, DeMatos P, Hester D, Dong XD, Seigler HF . Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280–288), induce pairs of T cell cultures with similar phenotype and lytic activity Cell Immunol 1998 186: 63–74
Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK . Migration of human dendritic cells after injection in patients with metastatic malignancies Cancer Res 1999 59: 56–58
Tarte K, Olsen SJ, Lu ZY, Legouffe E, Rossi JF, Chang Y, Klein B . Clinical grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus Blood 1998 91: 1852–1857
Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA . Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA Int J Cancer 1999 82: 121–124
Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, Deleo AB . Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells Clin Cancer Res 1999 5: 1281–1288
Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL, Jr, Wagner SN, Van der Bruggen P, Baar J, Lotze MT, Storkus WJ . Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1- biasing cytokines IL-12 and IFN-alpha J Immunol 1998 160: 1139–1147
Tarte K, Lu ZY, Fiol G, Legouffe E, Rossi JF, Klein B . Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma Blood 1997 90: 3482–3495
Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B . Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma Blood 1994 83: 3654–3663
Kalinski P, Schuitemaker JHN, Hilkens CMU, Wierenga EA, Kapsenberg ML . Final maturation of dendritic cells is associated with impaired responsiveness to IFN-g and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells J Immunol 1999 162: 3231–3236
Snijders A, Kalinski P, Hilkens CMU, Kapsenberg ML . High-level IL-12 production by human dendritic cells requires 2 signals Int Immunol 1998 10: 1593–1598
Toungouz M, Quinet C, Thille E, Fourez S, Pradier O, Delville JP, Velu T, Lambermont M . Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients Cytotherapy 1999 6: 447–453
Tarte K, Klein B . Dendritic-based vaccine: a promising approach for cancer immunotherapy Leukemia 1999 13: 653–664
Fujii S, Fujimoto K, Shimizu K, Ezaki T, Kawano F, Takatsuki K, Kawakita M, Matsuno K . Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients Cancer Res 1999 59: 2150–2158
Nazaruk RA, Rochford R, Hobbs MV, Cannon MJ . Functional diversity of the CD8+ T cell response to Epstein–Barr virus (EBV): implication for the pathogenesis of EBV-associated lymphoproliferative disorders Blood 1998 91: 3875–3883
Carter L, Dutton RW . Type 1 and type 2: a fundamental dichotomy for all T cell subsets Curr Opin Immunol 1996 8: 336–342
Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH . Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells Blood 1999 93: 1634–1642
Kalinski P, Schuitemaker JHN, Hilkens CMU, Kapsenberg ML . Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation J Immunol 1998 161: 2804–2809
Cella M, Scheidegger D, Palmer Lehmann K, Lane P, Lanzavecchia A, Alber G . Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation J Exp Med 1996 184: 747–752
Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ . Reciprocal control of T helper cell and dendritic cell differentiation Science 1999 283: 1183–1186
Zhou LJ, Tedder TF . A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells Blood 1995 86: 3295–3301
Acknowledgements
This work was supported by grants from the Ligue Nationale Contre le Cancer, ‘Equipe labellisée’ (Paris, France).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tarte, K., Fiol, G., Rossi, JF. et al. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia 14, 2182–2192 (2000). https://doi.org/10.1038/sj.leu.2401925
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401925
Keywords
This article is cited by
-
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Cancer Communications (2019)
-
Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity
Leukemia (2017)
-
Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
Cancer Immunology, Immunotherapy (2010)
-
Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture
Cancer Immunology, Immunotherapy (2008)
-
CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
Leukemia (2001)